Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPA Supplementation for CAD Risk in Schizophrenia
NCT00167310Phase 2Completed
- Sponsor
- University of Pittsburgh
- Start
- Sep 2005
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eicosapentaenoic acid in coronary artery disease (CAD), sponsored by University of Pittsburgh. Started Sep 2005; status: completed.
02
Drugs
eicosapentaenoic acid
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00167310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00167310.